Upregulation of ACE/ACE 2 balance in nasal mucosa: A working hypothesis to explain the absence

Upregulation of ACE/ACE2 Balance in Nasal Mucosa: A Working Hypothesis to Explain the Absence of Nasal Inflammatory Symptoms in COVID-19 DiseaseAmit Jain, MD¹

, and Massimo Lamperti, MD¹Ear, Nose & Throat Journal
2023, Vol. 102(10) 680 –681
© The Author(s) 2021
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/01455613211025747
journals.sagepub.com/home/earimg1
KeywordsCOVID-19, nasal symptoms in COVID-19, SARS-CoV-2, epithelial–endothelial cross talk in COVID-19We read with interest the article by Sayin et al, debating the significance of the paucity of nasal symptomatology, except for anosmia, in COVID-19.¹ However, the authors didn’t provide any pathophysiological mechanism for this low incidence of sneezing, rhinorrhea, nasal obstruction, and sinusitis-like manifestations of the usual viral rhinitis in COVID-19. We, herein, take an opportunity to explain these differences based on our “epithelial-endothelial cross-talk hypothesis” of COVID-19 pneumonia.²Bradykinin is believed to have a major role in generating the usual local symptoms of upper respiratory tract infections.³ However, in severe acute respiratory syndrome and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we believe that bradykinin formation is largely inhibited due to the upregulation of ACE-Ang II-AT1R pathways. It has been shown that SARS-CoV-2 spike protein binds with membranous angiotensin-converting enzyme 2 (ACE2) of ciliated nasal epithelial cells and sustentacular cells in olfactory epithelium and can result in downregulation and shedding of ACE2 on the airway epithelium. This can possibly result in relative upregulation of ACE-Ang II-AT1R activity in nasal mucosa. Undoubtably, this effect in the nasal mucosa should be less pronounced than at the alveolar capillary ultrastructure due to less pronounced epithelial–endothelial cross talk. Note, on immunohistochemistry, ACE has been localized on the endothelial cells of the fenestrated capillaries in the superficial lamina propria, beneath the basement membrane, of the ciliated, pseudostratified, columnar epithelium of human nasal mucosa, and in the nasal epithelial lining fluid.⁴ Although the precise role of ACE in mucosal health and disease is unknown, based on their observations, Ohkubo et al proposed that ACE may participate in the respiratory inflammatory diseases by limiting the levels of inflammatory peptides such as bradykinin and substance P, thus suggested its protective role against viral rhinitis.⁴ Hence, there is possibility that the indirect upregulation of ACE-Ang-II pathways in the nasal mucosa can promote bradykinin degradation and cause vasoconstriction; thus, minimizing nasal congestion in SARS-CoV-2 infection. Also, as SARS-CoV-2 can replicate to high levels without inducing substantial host cell damage,⁵ direct injury to the ciliated nasal mucosal cells as a result of infective process is minimal. This is in contrast to the previous coronaviruses that accounts for 15% to 30% of common cold and carries a greater potential to produce significant nasal epithelial disruption by direct infective process,⁶ thus cause extensive bradykinin formation from tissue injury. Further, as SARS-CoV-2 inhibits innate immune response,⁷ the immune-mediated indirect injury of nasal epithelium is minimal.Our arguments are further supported by the fact that asthma did not increase the risk of developing severe COVID-19.⁸ This is in contrast to H1NI pneumonia, wherein asthma was the strongest risk predictor. Further, wheezing is uncommon in patients with COVID-19 pneumonia.⁹ If “bradykinin storm” is believed to be the pathophysiological explanation of COVID-19 disease, wheeze and nasal symptoms of rhinorrhea, congestion, and sinusitis should be common.Our hypothesis is also supported by the recent publication of Navarra et al reporting “excessive nasal dryness” and/or a continual sensation of having had a “nasal douche” in 61.8% and 51.5% of the COVID-19 patients.¹⁰ We believe that the hypothesis of ACE-AngII-AT1R upregulation mediated mechanisms can support these symptoms as well.Authors’ NoteSupport was provided solely from institutional and/or departmental sources.ORCID iDAmit Jain

https://orcid.org/0000-0002-0012-9491
References

Sayin I, Yazici ZM, Akgül A. Local nasal response against COVID-19: debate regarding the absence of nasal inflammatory symptoms. Ear Nose Throat J. 2021. PMID:33530741. doi:10.1177/0145561321992505

Jain A, Doyle DJ. Stages or phenotypes? A critical look at COVID-19 pathophysiology. Intensive Care Med. 2020;46(7): 1494-1495. PMID:32424481. doi:10.1007/s00134-020-06083-6

Eccles R. Understanding the symptoms of the common cold and influenza. Lancet Infect Dis. 2005;5(11):718-725. PMID: 16253889. doi:10.1016/S1473-3099(05)70270-X

Ohkubo K, Lee CH, Baraniuk JN, Merida M, Hausfeld JN, Kaliner MA. Angiotensin-converting enzyme in the human nasal mucosa. Am J Respir Cell Mol Biol. 1994;11(2):173-180. PMID:8049077. doi:10.1165/ajrcmb.11.2.8049077

Chu H, Chan JF, Yuen TT, et al. Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study. Lancet Microbe. 2020;1(1):e14-e23. PMID:32835326. doi:10.1016/S2666-5247(20)30004-5

Chilvers MA, McKean M, Rutman A, Myint BS, Silverman M, O’Callaghan C. The effects of coronavirus on human nasal ciliated respiratory epithelium. Eur Respir J. 2001;18(6): 965-970. PMID:11829103. doi:10.1183/09031936.01.00093001

XiaH,CaoZ,XieX,etal.Evasionoftypeiinterferonby SARS-CoV-2. Cell Rep. 2020;33(1):108234. PMID:32979938. doi:10.1016/j.celrep.2020.108234

Wu T, Yu P, Li Y, et al. Asthma does not influence the severity of COVID-19: a meta-analysis. J Asthma. 2021;23:1-7. PMID: 33863266. doi:10.1080/02770903.2021.1917603

Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK. Lancet Respir Med. 2021; S2213-2600(21). PMID: 33676593. doi:10.1016/S2213-2600(21)00013-8

Navarra J, Ruiz-Ceamanos A, Moreno JJ, et al. Acute nasal dryness in COVID-19. medRxiv. 2020. doi:10.1101/2020.11.18.20233874

¹ Anesthesiology Institute, Cleveland Clinic Abu Dhabi, United Arab EmiratesReceived: May 23, 2021; accepted: May 27, 2021Corresponding Author:
Amit Jain, MD, Anesthesiology Institute, Cleveland Clinic Abu Dhabi, Al Maryah Island, PO Box 112412, Abu Dhabi 112412, United Arab Emirates.
Email: amitvasujain@gmail.comJournal CoverSage Deep BackfileXlear IncEB1Wexner Medical CenterEB2IACCANT CorpAuthor ServicesA Sweet Voice: Acute Febrile Neutrophilic Dermatosis of the LarynxClival mucocele: a rare yet not forgotten pathologyOligometastatic parathyroid carcinoma presenting as neck pain: a case report.Intravascular papillary endothelial hyperplasia (Masson's tumor) of the submandibular glandThe Diagnostic Yield of Excision Biopsy in Cervical Lymphadenopathy: A Retrospective AnalysisRectal S. aureus Carriage and Recurrence after Endoscopic Sinus Surgery for Chronic RhinosinusitisThe Impact of Surgical Posterior Nasal Nerve Cryoablation on Symptoms and Disease-SpecificComprehensive analysis of the diagnosis and treatment of tracheobronchial foreign bodies in childrenManagement Strategy of Local Subcutaneous Effusion After Auricle ReconstructionOutcomes of Mastoidectomy with Antibiotic Catheter Irrigation for Patients with DrainingUpregulation of ACE/ACE 2 balance in nasal mucosa: A working hypothesis to explain the absenceOnline Only Cover PageA retrospective review of 589 percutaneous tracheostomies in a Canadian community teaching hospitalVersoMcKeon Products